Public Release: 

How live vaccines enhance the body's immune response

New findings point the way to more efficient vaccines

Charité - Universitätsmedizin Berlin

IMAGE

IMAGE: This is an immunofluorescence image of cells inside a lymphoid follicle. B cells are depicted in red, cell nuclei in blue. Yellowish-green staining denotes cells of the germinal center (where... view more 

Credit: Freie Universitaet Berlin, Kristina Dietert

Researchers from Charité - Universitätsmedizin Berlin, Berlin's university hospital, have discovered a new mechanism by which live vaccines induce immunity. Molecules produced exclusively by live microorganisms are recognized by specialized receptors of the immune system, subsequently triggering a protective immune response. The new findings may help improve the safety and efficacy of vaccines. Results from this study have been published in the journal Nature Immunology*.

Vaccines exploit the immune system's ability to 'memorize' encounters with previously unknown microbes. Once 'educated' in such a way by vaccination, the immune system is much more swift and effective in fighting off future infections by the same pathogen. Live attenuated vaccines have been successfully used since 1798, yet little is known about what makes them so effective and their inherent superiority over inanimate vaccines. Together with several collaborators, Prof. Leif Erik Sander and his team at Charité's Department of Infectious Diseases and Pulmonary Medicine set out to dissect the underlying mechanisms of this phenomenon.

The immune system is charged with detecting microbial invaders, which are ingested by specialized immune cells, and broken down inside specialized organelles. In contrast to inactivated (killed) vaccines, live vaccines contain metabolically active microbes, which produce a wide range of different molecules. Ribonucleic acid (RNA) is one of the molecules produced by live microorganisms, which essentially marks them as viable. During the process of digestion, the RNA of a pathogen or a live vaccine is bound by a specific type of immune receptor known as Toll-like receptor 8 (TLR8). Binding of RNA to TLR8 triggers an immunological chain reaction eventually culminating in a robust antibody response. TLR8 induced signals call into action a specialized type of immune cell known as follicular helper cells. These helper cells critically support the immune system's B cells and help them to mature into so called plasma cells, which are cellular factories for antibody production. These new findings will enable researchers to use targeted vaccine adjuvants to activate follicular helper cells and thus antibody responses. Adjuvants are often added to vaccines to increase the body's immune response, however, current adjuvant formulations are often non-specific in their action.

In their study, Prof. Sander and his team compared immune responses mounted against live and killed bacteria, using cell culture systems with human immune cells. The researchers found that live bacteria elicited slightly altered immune responses within the innate immune system. While the changes were moderate, they had striking effects on the 'adaptive' (acquired) arm of the immune response, which is responsible for the production of antibodies and for long-term protection following vaccination. Moreover, the scientists also found that patients carrying an activating TLR8 gene variant responded better to a live vaccine against tuberculosis, which resulted in improved protection against disease. These results suggest that TLR8 acts as a key switch for protective immune responses.

"Our immune system responds differently to killed and live vaccines. This is caused by the detection of RNA within live microorganisms via TLR8, which in turn triggers protective immune responses" explains Leif Erik Sander, the study's principal investigator. Given the drastic increase in the rates of antibiotic resistance both in veterinary and human medicine, new vaccines against dangerous, resistant bacteria are urgently needed. "These results may enable us to develop new vaccines that will combine the safety of modern subunit vaccines with the high efficacy of live vaccines." The researchers are currently dissecting the immune responses to the measles vaccine virus, and they are working with the Max Planck Institute of Colloids and Interfaces to develop new vaccines against pneumonia.

###

* Ugolini M, et al. Recognition of microbial viability via TLR8 drives

TFH cell differentiation and vaccine responses. Nature Immunology 2018. doi: 10.1038/s41590-018-0068-4.

Contact:

Prof. Dr. Leif Erik Sander
Department of Infectious Diseases and Pulmonary Medicine
Charité - Universitätsmedizin Berlin
Tel: +49 30 450 653 034
Email: leif-erik.sander@charite.de

Links:

- Medical Department, Division of Infectiology and Pneumonology http://infektiologie-pneumologie.de/en/

- Leif Erik Sander's Laboratory | Website http://www.charite-inflab.de/sander-lab/

- Leif Erik Sander's Laboratory | Twitter https://twitter.com/Sander_Lab

- Full text of the original article: http://rdcu.be/JnYh

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.